Tuvonralimab
Autosomal Dominant Parkinson Disease 1
Explore 7 assets in Autosomal Dominant Parkinson Disease 1 →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Anhui Provincial Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07128251CT.gov A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | — | Not Yet Recruiting | — | — | — |
NCT07131501CT.gov A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autosomal Dominant Parkinson Disease 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuvonralimab (this asset) | Anhui Provincial Hospital | P2 | CCC · 53 |
| Lenvatinib | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC |
| f520 | Shandong New Time Pharmaceutical Co., LTD | P2 | CCC |
| Ruxoprubart | Shanghai Pulmonary Hospital, Shanghai, China | P2 | CCC |
| Dasatinib | The Affiliated Hospital of Qingdao University | P2 | CCC |
| Carboplatin | Shandong New Time Pharmaceutical Co., LTD | P2 | CCC |
| pd-1 knockout engineered t cells | Ruijin Hospital | P1 | CC |
| pd1-til | Ruijin Hospital | P1 | CC |
Other indications for Tuvonralimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Autoimmune Pulmonary Disease Due To PD-1 Deficiency | — | P4 | BB · 65 |
| Melanoma | — | P4 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tuvonralimab in Autosomal Dominant Parkinson Disease 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tuvonralimab-autosomal-dominant-parkinson-disease-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →